AI-Powered Colorectal Cancer Research

Metastatic colorectal cancer requires multi-modality approaches. AI agents research microsatellite instability-based immunotherapy, BRAF-targeted combinations, and emerging compounds.

Get a $99 personalized brief on Colorectal Cancer

14 specialist agents compile a 30–50 page brief from PubMed-indexed research, delivered in 48 hours. Refund + free re-brief if not useful.

Standard of Care

FOLFOX/FOLFIRI + bevacizumab or cetuximab (RAS wild-type), pembrolizumab (MSI-H), encorafenib + cetuximab (BRAF V600E).

Prevalence

~153,000 new colorectal cancer diagnoses per year in the US. 2nd leading cause of cancer death.

Five-Year Survival

Stage IV: ~14%. MSI-H with immunotherapy: significantly higher.

Key Mutations

KRAS/NRAS
BRAF V600E
MSI-H/dMMR
HER2 amplification
PIK3CA

Key Pathways

kras-mapk
wnt-beta-catenin
vegf-angiogenesis
pd-1-pd-l1

Clinical Trial Focus

ctDNA-guided adjuvant therapy, HER2-targeted ADCs, KRAS G12C inhibitors, bispecific T-cell engagers.